Video Article

Stereotaxic Injection of a Viral Vector for Conditional Gene Manipulation in the Mouse Spinal Cord

Perrine Inquimbert¹, Martin Moll², Tatsuro Kohno³, Joachim Scholz²

¹Département Nociception et Douleur, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique (CNRS)

²Departments of Anesthesiology and Pharmacology, Columbia University

³Department of Anesthesiology, Niigata University Graduate School of Medical and Dental Sciences

Correspondence to: Joachim Scholz at js3932@mail.cumc.columbia.edu

URL: <http://www.jove.com/video/50313>

DOI: [doi:10.3791/50313](https://doi.org/10.3791/50313)

Keywords: Neuroscience, Issue 73, Neurobiology, Genetics, Biomedical Engineering, Bioengineering, Anatomy, Physiology, Virology, Molecular Biology, Cellular Biology, Spinal Cord, Stereotaxic Techniques, Genetic Vectors, mouse spinal cord, dorsal horn, stereotaxic injection, viral vector, transgenic, gene expression, transfection, neurons, GFP, immunostaining, animal model

Date Published: 3/18/2013

Citation: Inquimbert, P., Moll, M., Kohno, T., Scholz, J. Stereotaxic Injection of a Viral Vector for Conditional Gene Manipulation in the Mouse Spinal Cord. *J. Vis. Exp.* (73), e50313, doi:10.3791/50313 (2013).

Abstract

Intraparenchymal injection of a viral vector enables conditional gene manipulation in distinct populations of neurons or particular regions of the central nervous system. We demonstrate a stereotaxic injection technique that allows targeted gene expression or silencing in the dorsal horn of the mouse spinal cord. The surgical procedure is brief. It requires laminectomy of a single vertebra, providing for quick recovery of the animal and unimpaired motility of the spine. Controlled injection of a small vector suspension volume at low speed and use of a microsyringe with beveled glass cannula minimize the tissue lesion. The local immune response to the vector depends on the intrinsic properties of the virus employed; in our experience, it is minor and short-lived when a recombinant adeno-associated virus is used. A reporter gene such as enhanced green fluorescent protein facilitates monitoring spatial distribution of the vector, and the efficacy and cellular specificity of the transfection.

Video Link

The video component of this article can be found at <http://www.jove.com/video/50313/>

Introduction

Advanced technologies of conditional gene manipulation in the mouse enable multifaceted approaches to the exploration of synaptic pathways and functional connections in the central nervous system. Transgenes may be regulated by small-molecule effectors such as doxycycline acting on a tetracycline-controlled transactivator, which can be designed to function as a repressor or an activator of gene transcription, or tamoxifen recognizing a mutated ligand-binding domain of the estrogen receptor¹. Irreversible transgene modification is commonly achieved by deoxyribonucleic acid (DNA) recombinases. Cre (causes recombination) and Flp (flippase recombination enzyme) catalyze the excision, inversion or translocation of DNA fragments that are flanked by loxP (locus of crossing x over, P1) or Frt (flippase recognition target) sites, respectively¹. Applications include gene activation or silencing and inducible ribonucleic acid (RNA) interference². Conditional expression of fluorescent or enzymatic reporters such as β -galactosidase or alkaline phosphatase can be used to label neurons and examine their topical organization and connectivity³. Large-scale mutagenesis projects in North America (<http://www.norcomm.org/index.htm>) and Europe (<http://www.knockoutmouse.org/about/eucomm>) are producing libraries of mouse embryonic stem cell clones with conditional gene targets and traps that will eventually cover the entire mouse genome. Mice generated from these clones may be crossed with an expanding number of mouse lines that express DNA recombinases under promoters or loci specific to a particular population of neurons for selective gene manipulation (http://nagy.mshri.on.ca/cre_new/index.php).

However, restricting gene manipulation to distinct populations of neurons or particular regions of interest may not be achieved by genetic targeting alone if a promoter specific to the neuron population of interest is not known or not expressed by all neurons in the region of interest. In the spinal cord, experimental designs may require spatial restriction of the gene manipulation to one or two craniocaudal segments. Stereotaxic injection of a viral vector that expresses Cre or Flp allows limiting gene recombination to regions in the spinal cord of mice in which DNA fragments are flanked by loxP or Frt sites, so-called floxed or flired alleles. Unlike constitutive DNA rearrangement, which would result from crossbreeding the animals with recombinase expressing mice, this strategy also provides temporal control over gene activation or silencing. Viral vectors encoding floxed or flired transgenes offer a reverse option of gene manipulation in mice expressing the corresponding recombinase downstream of a neuron-specific promoter. Several recombinant vectors with affinity to neurons are available⁴. High-capacity (gutless) adenovirus, adeno-associated virus, herpes simplex virus and lentivirus are commonly used neurotropic vectors. Selecting the appropriate virus for a research question is a crucial part of the experimental design. Size of the transgene, delivery route, specificity of the infection to neurons as opposed to glial cells, infection efficacy, inflammatory and toxic side effects need to be considered⁴.

Here we describe the stereotaxic injection of a viral vector into the dorsal horn of the spinal cord, a technique that we employ for conditional gene regulation in our research on the neurobiology of pain. The dorsal horn receives afferent input from primary somatosensory neurons including nociceptive neurons. Local interneurons process the information before projection neurons convey it from the dorsal horn to the brain⁵. We demonstrate the infection of dorsal horn neurons at spinal segmental level L4 with a neurotropic recombinant adeno-associated virus (rAAV) that expresses enhanced green fluorescent protein (eGfp) under a constitutively active cytomegalovirus promoter.

Protocol

The surgical procedure described has been approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University.

1. Preparation of Equipment and Virus Particle Suspension

1. Clean and disinfect the equipment, sterilize the surgical instruments and the V notch spikes that will be used to fix vertebra L1.
2. Pull and bevel glass pipettes. We use pipettes that have a tip diameter of 40 μm and are beveled at an angle of 20°. Sterilize the glass pipettes.
3. Set up the stereotaxic frame, mount the microsyringe injector onto the manipulator and connect the injector to the controller.
4. Attach one of the glass pipettes to the microsyringe using the compression fitting kit.
5. Remove the plunger from the microsyringe and fill the syringe with mineral oil. Oil Red O (1-(2,5-dimethyl-4-(2,5-dimethylphenylazo)phenylazo)-2-naphthol) may be added to the mineral oil to increase its visibility. Reinsert the plunger and push it to all the way to the tip. Carefully avoid creating an air bubble.
6. Prepare the virus particle suspension in a biosafety cabinet. Thaw the frozen virus on ice and, just before use, dilute it with sterile phosphate-buffered saline to the desired particle concentration.
7. Insert the microsyringe into the holder on the injector.
8. Pipette 5 μl of the virus suspension onto a small plastic sheet, e.g. Parafilm. Lower the glass pipette tip into the drop and pull the plunger to fill the microsyringe. Create a small air bubble at the pipette tip to prevent it from clogging.

2. Laminectomy

1. Prepare the surgery area by wiping bench and heating pad with disinfectant.
2. Anesthetize the mouse. We use inhalation anesthesia with isoflurane (3% during induction, 2%-3% during maintenance).
3. Place lubricant on each eye to protect the eyes from drying during the operation.
4. Shave the fur from the lower back to the neck of the mouse and disinfect the skin with alternating wipes of a topical antiseptic such as chlorhexidine or povidone-iodine and 70% ethanol. Isolate the aseptically prepared site with surgical drape and infiltrate the incision site with bupivacaine (0.25%, diluted 1:10 with physiological saline).
5. Incise the skin at the caudal end of the rib cage along the midline (2-3 cm) and separate the fascia covering the spine.
6. Because the spinal cord stops growing earlier during postnatal development than the vertebral column, spinal segment L4 lies underneath the first lumbar vertebra (L1). Vertebra L1 is located caudal to the vertebra that holds the last pair of ribs. Identify and expose vertebra L1 by removing the small spinal muscles and ligaments attached to its dorsal surface.
7. Slightly lift and hold vertebra L1 with an Adson forceps. Use a dedicated laminectomy forceps to remove the dorsal portion of the vertebra (spine and lamina) and expose the spinal cord. Avoid damaging the spinal cord.
8. Transfer the mouse onto the heating plate in the stereotaxic frame. Monitor the temperature of the mouse during the subsequent operation.

3. Injection

1. Fix vertebra L1 with V notch spikes. The spikes must stabilize the spine so that the vertebra does not move during breathing.
2. Bring the microsyringe closer so that the pipette tip is above the laminectomy site. Lower the plunger until you see the virus suspension exiting the pipette. Remove the droplet with a sterile cotton tip.
3. Position the pipette tip at the rostral-most portion of the exposed spinal cord. Center the pipette above the posterior median sulcus, then move the tip 500 μm laterally. Lower the tip to the surface of the cord and puncture the dura mater or, if you are working with an unbeveled glass pipette, use a beveled steel cannula to puncture the dura. Lower the tip of the glass pipette 300 μm into the spinal cord.
4. Inject 1 μl of virus suspension at a rate of 200 nl/min.
5. At the end of the injection, wait at least 2 min before slowly retracting the pipette.
6. Repeat steps 3.3 to 3.5 at the caudal-most portion of the exposed spinal cord to achieve complete distribution of the viral vector in spinal segment L4. The two injection sites are located rostral and caudal of the L4 segment to avoid tissue damage in the target region.

4. Wound Closure

1. Release vertebra L1 from the V notch clamps and remove the mouse from the stereotaxic frame.
2. Suture the fascia with 5.0 vicryl. The closed fascia provides cover for the laminectomy site.
3. Close the skin with nylon sutures or surgical staples.

5. Postoperative Care

1. Transfer the mouse to a recovery cage with soft, nonparticulate bedding. Place it on the side for comfortable breathing. Monitor the animal until it is fully alert, ambulant and starts drinking.
2. We provide postsurgical analgesia for 72 hr with daily subcutaneous injections of carprofen (5.0 mg/kg).

3. Monitor postsurgical recovery by daily inspection for the first 3 days, then every other day or 3 days per week until the experiment is complete.
4. Remove the skin sutures or staples 7 to 10 days after the operation, when wound healing is complete.
5. Euthanize the animal after completion of the experiment.

Representative Results

Successful transfection yields robust gene expression in neurons of the injected dorsal horn (**Figure 1**), sparing the dorsal horn of the contralateral side, the ventral horn and the dorsal root ganglia.

Figure 1. Transfection of dorsal horn neurons. (A) Expression of the fluorescent reporter eGfp (green) in the left dorsal horn of the L4 spinal cord, two weeks after the stereotaxic injection of rAAV-eGfp (serotype AAV2/8, 10^9 genome copies/ μ l). Neurons were immunostained for neuronal nuclei protein (NeuN, red). Arrow heads point to scattered transfected glial cells in the dorsal column. Scale bar, 150 μ m. (B) Approximately 80% of neurons in the medial dorsal horn were infected. Scale bar, 20 μ m. A monoclonal antibody against NeuN (EMD Millipore) was used at a dilution of 1:2,000 for the immunostaining.

Discussion

Stereotaxic vector injection allows targeting spinal cord neurons for applications such as neuronal network mapping based on transsynaptic virus spreading^{6,7} or optogenetic dissection⁸, axon guidance during regeneration from injury^{9,10}, or gene therapy for the prevention or treatment of neurodegeneration^{11,12}. Viral vectors have been used for gene manipulation in the spinal cord to study somatosensory, motor and autonomic pathways^{9,10,13-15}. The mouse is the model organism most widely used in studies involving stereotaxic injection of a viral vector into the brain or the spinal cord, but the technique has been employed in other species including nonhuman primates¹⁶.

Stereotaxic vector injection into the mouse spinal cord is safe; the surgical procedure described here requires a single laminectomy at the injection site so that the animal recovers without instability in its spine movements. Injection and slow removal of the cannula are complete within 10 min, the entire procedure including skin preparation and wound closure lasts approximately 40 min. We provide postsurgical anesthesia for 72 hr with carprofen, a nonsteroidal anti-inflammatory analgesic drug.

To minimize tissue trauma, we employ pulled glass cannulas with a tip diameter of 40 μ m. A sharp beveled cannula tip eases insertion into the spinal cord, justifying the investment in a micropipette grinder. Use of a grinder also allows maintaining a consistent bevel angle in each experiment, reducing variation of the injection results. We prefer automated control of the injection speed over manual dispensation¹⁷ for an even distribution of the virus particle suspension in the dorsal horn and to reduce the risk of an injection error. Equally critical is a slow extraction of the cannula, which should be initiated 2-5 min after completing the injection to avoid drawing the virus suspension back up and causing an extraspinal spill.

Extent and distribution of the intraspinal transfection depend on the injected particle dose and intrinsic properties of the viral vector such as serotype and infection efficacy. The optimal particle dilution has to be determined empirically for each virus and serotype and may vary between

different batches of the same virus. Efficacy of both infection and DNA transduction may also differ depending on the targeted population of neurons^{18,19}. AAV achieves gene transfer in neurons without pathogenic and minimal immune side effects²⁰. In our experience, the infection of dorsal horn neurons is complete within 1-2 weeks and stable. We have observed minor microglial responses at injection sites but these resolved within one week.

We recommend comparing different serotypes of vectors that express a reporter gene such as eGfp to evaluate transfection rates, determine the time intervals between injection and stable transfection and establish whether the infection is limited to neurons. Specificity will depend on the cell tropism of the vector, the transfected gene and its promoter. Investigators studying somatosensory pathways should also examine dorsal root ganglion neurons for a potential expression of the reporter gene, which may result from infection of these neurons at their central terminals in the dorsal horn or from contamination of the cerebrospinal fluid¹⁹.

In the United States, the use of viral vectors for gene manipulation is regulated by the NIH Guidelines for Research Involving Recombinant DNA Molecules (http://oba.od.nih.gov/rdna/nih_guidelines_oba.html). These Guidelines stipulate requirements for investigator training, personal protection, viral vector containment, decontamination, disposal of contaminated materials such as used syringes and cannulas, and animal housing after the injection. Investigators should work with their local IACUC or equivalent body of institutional oversight to determine the rules and regulations that apply to their research.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

We thank Bakhos A. Tannous, Ph.D., Director of Vector Development and Production in the Neuroscience Center of Massachusetts General Hospital, Charlestown, Massachusetts, for providing us with the rAAV-eGfp vector, and John Whang for technical assistance. This work was supported by grant R01 NS050408 (to J.S.) from the National Institute of Neurological Disorders and Stroke.

References

- Lewandoski, M. Conditional control of gene expression in the mouse. *Nature Reviews Genetics*. **2**, 743-755, doi:10.1038/35093537 (2001).
- Couto, L.B. & High, K.A. Viral vector-mediated RNA interference. *Curr. Opin. Pharmacol.* **10**, 534-542, doi:10.1016/j.coph.2010.06.007 (2010).
- Luo, L., Callaway, E.M., & Svoboda, K. Genetic dissection of neural circuits. *Neuron*. **57**, 634-660, doi:10.1016/j.neuron.2008.01.002 (2008).
- Davidson, B.L. & Breakefield, X.O. Viral vectors for gene delivery to the nervous system. *Nature Reviews Neuroscience*. **4**, 353-364, doi:10.1038/nrn1104 (2003).
- Todd, A.J. Neuronal circuitry for pain processing in the dorsal horn. *Nature Reviews Neuroscience*. **11**, 823-836, doi:10.1038/nrn2947 (2010).
- Wall, N.R., Wickersham, I.R., Cetin, A., De La Parra, M., & Callaway, E.M. Monosynaptic circuit tracing *in vivo* through Cre-dependent targeting and complementation of modified rabies virus. *Proceedings of the National Academy of Sciences of the United States of America*. **107**, 21848-21853, doi:10.1073/pnas.1011756107 (2010).
- Lo, L. & Anderson, D.J. A Cre-dependent, anterograde transsynaptic viral tracer for mapping output pathways of genetically marked neurons. *Neuron*. **72**, 938-950, doi:10.1016/j.neuron.2011.12.002 (2011).
- Zhao, S., *et al.* Cell type-specific channelrhodopsin-2 transgenic mice for optogenetic dissection of neural circuitry function. *Nature Methods*. **8**, 745-752 (2011).
- Tang, X.Q., Heron, P., Mashburn, C., & Smith, G.M. Targeting sensory axon regeneration in adult spinal cord. *J. Neurosci.* **27**, 6068-6078, doi:10.1523/JNEUROSCI.1442-07.2007 (2007).
- Cameron, A.A., Smith, G.M., Randall, D.C., Brown, D.R., & Rabchevsky, A.G. Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. *J. Neurosci.* **26**, 2923-2932, doi:10.1523/JNEUROSCI.4390-05.2006 (2006).
- Passini, M.A., *et al.* CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. *The Journal of Clinical Investigation*. **120**, 1253-1264, doi:10.1172/JCI41615 (2010).
- Lutz, C.M., *et al.* Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. *The Journal of Clinical Investigation*. **121**, 3029-3041, doi:10.1172/JCI57291 (2011).
- Chen, S.L., *et al.* dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 20096-20101, doi:10.1073/pnas.0703409104 (2007).
- South, S.M., *et al.* A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. *J. Neurosci.* **23**, 5031-5040, [pii] 23/12/5031 (2003).
- Tappe, A., *et al.* Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain. *Nat. Med.* **12**, 677-681, doi:10.1038/nm1406 (2006).
- Colle, M.A., *et al.* Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. *Human Molecular Genetics*. **19**, 147-158, doi:10.1093/hmg/ddp475 (2010).
- Carbajal, K.S., Weinger, J.G., Whitman, L.M., Schaumburg, C.S., & Lane, T.E. Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus. *J. Vis. Exp.* (53), e2834, doi:10.3791/2834 (2011).
- Snyder, B.R., *et al.* Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. *Hum. Gene Ther.* **22**, 1129-1135, doi:10.1089/hum.2011.008 (2011).
- Towne, C., Pertin, M., Beggah, A.T., Aebischer, P., & Decosterd, I. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. *Mol. Pain*. **5**, 52, doi:10.1186/1744-8069-5-52 (2009).

20. Kaplitt, M.G., *et al.* Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. *Nat. Genet.* **8**, 148-154, doi:10.1038/ng1094-148 (1994).